The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)

· 2020-01-13

Abstract

Repeated exposure to the acute proinflammatory environment that follows ovulation at the ovarian surface and distal fallopian tube over a woman's reproductive years may increase ovarian cancer risk. To address this, analyses included individual-level data from 558,709 naturally menopausal women across 20 prospective cohorts, among whom 3,246 developed invasive epithelial ovarian cancer (2,045 serous, 319 endometrioid, 184 mucinous, 121 clear cell, 577 other/unknown). Cox models were used to estimate multivariable-adjusted HRs between lifetime ovulatory cycles (LOC) and its components and ovarian cancer risk overall and by histotype. Women in the 90th percentile of LOC (>514 cycles) were almost twice as likely to be diagnosed with ovarian cancer than women in the 10th percentile (<294) [HR (95% confidence interval): 1.92 (1.60–2.30)]. Risk increased 14% per 5-year increase in LOC (60 cycles) [(1.10–1.17)]; this association remained after adjustment for LOC components: number of pregnancies and oral contraceptive use [1.08 (1.04–1.12)]. The association varied by histotype, with increased risk of serous [1.13 (1.09–1.17)], endometrioid [1.20 (1.10–1.32)], and clear cell [1.37 (1.18–1.58)], but not mucinous [0.99 (0.88–1.10), P-heterogeneity = 0.01] tumors. Heterogeneity across histotypes was reduced [P-heterogeneity = 0.15] with adjustment for LOC components [1.08 serous, 1.11 endometrioid, 1.26 clear cell, 0.94 mucinous]. Although the 10-year absolute risk of ovarian cancer is small, it roughly doubles as the number of LOC rises from approximately 300 to 500. The consistency and linearity of effects strongly support the hypothesis that each ovulation leads to small increases in the risk of most ovarian cancers, a risk that cumulates through life, suggesting this as an important area for identifying intervention strategies.

Significance:

Although ovarian cancer is rare, risk of most ovarian cancers doubles as the number of lifetime ovulatory cycles increases from approximately 300 to 500. Thus, identifying an important area for cancer prevention research.

Funding
Community Outreach and EngagementCancer Research UK Grant C570/A16491Medical Research Council Grant MR/N003284/1The NYU Women's Health StudyMedical Research Council Grant G1000143Administrative CoreMedical Research Council Grant 1000143PCOS, Type II diabetes and ovarian cancer riskEpidemiology of Cancer in a Cohort of Older WomenMedical Research Council Grant G0401527Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyBreast and Other Cancers in the California Teachers CohortWomen's Health Study: Continued Follow-upWomen's Health Study: Continued Follow-UpWomen's Health Study: Infrastructure support for cohort follow-upEnvironmental and Genetic Risk Factors For Breast Cancer: The Sister StudyCore A: Biospecimen and High-Dimensional Data Management CoreCancer Research UK Grant 14136Therapeutic and Diagnostic Factors as Related to Cancer RiskTRIAL OF ASPIRIN AND VITAMIN E IN WOMENEstablished Investigator Award Anti-Inflammatory Exposures in Cancer PreventionCancer Research UK Grant C8221/A19170Medical Research Council Grant MR/M012190/1The Women's Health Study: Infrastructure Support for Continued Cohort Follow-upThe Women's Health Study: Addition of New Data to Maximize its Research ImpactTherapeutic and Diagnostic Factors as Related to Cancer RiskCancer Biology Research ProgramWorld Health Organization Grant 001Understanding Population Differences in Cancer: The MEC StudyDepartment of Defense Ovarian Cancer Research Grant W81XWH-12-1-0561PCOS, Type II diabetes and ovarian cancer riskEnvironmental and Genetic Risk Factors For Breast Cancer: The Sister StudyBreast and Other Cancers in the California Teachers CohortUnderstanding Population Differences in Cancer: The MEC StudyCore A: Biospecimen and High-Dimensional Data Management CoreEpidemiology of Cancer in a Cohort of Older WomenWomen's Health Study: Continued Follow-upEstablished Investigator Award Anti-Inflammatory Exposures in Cancer PreventionTherapeutic and Diagnostic Factors as Related to Cancer Risk

NCI NIH HHS

P30 CA016087

NCI NIH HHS

UM1 CA182934

NIEHS NIH HHS

P30 ES000260

NCI NIH HHS

K22 CA193860

NCI NIH HHS

R01 CA039742

NCI NIH HHS

UM1 CA186107

NCI NIH HHS

R01 CA077398

NCI NIH HHS

R01 CA047988

NHLBI NIH HHS

R01 HL080467

NCI NIH HHS

U01 CA182913

Intramural NIH HHS

Z01 ES044005

NCI NIH HHS

P01 CA087969

Intramural NIH HHS

Z01 CP010128

NHLBI NIH HHS

R01 HL043851

NCI NIH HHS

K05 CA154337

NCI NIH HHS

UM1 CA182913

NHLBI NIH HHS

RC1 HL099355

Intramural NIH HHS

ZIA CP010128

NCI NIH HHS

P30 CA071789

NCI NIH HHS

U01 CA164973

HHS | NIH | National Cancer Institute

CA193860

HHS | NIH | National Institute of Environmental Health Sciences

Z01-ES044005

HHS | NIH | National Cancer Institute

CA077398

HHS | NIH | National Cancer Institute

CA164973

HHS | NIH | National Cancer Institute

CA087969

HHS | NIH | National Cancer Institute

CA039742

HHS | NIH | National Cancer Institute

CA047988

HHS | NIH | National Cancer Institute

CA154337

HHS | NIH | National Cancer Institute

CP010128